ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

No Matter the Money, I Want the Vaccine in December

Updated on July 29, 2020

No matter the money, I want the vaccine in December

Many countries are ordering in advance to get the corona vaccine in advance. The Trump administration has announced many large investments to get vaccinated. The country has signed a 2 billion US dollar deal with vaccine maker Pfizer and Bio N Tech to get 100 million doses of the vaccine by December.

The ‘New York Times’ reports that Pfizer has been contracted under the White House's ‘Rap Speed ​​Project’ as part of a rapid vaccination initiative. It is expected that the work of making and marketing the vaccine will be faster. So far, the United States has invested in six vaccines to increase vaccine production and innovation capabilities.

Like the United States, Europe is making various efforts to get vaccinated. Germany has already bought a 23 percent stake in the country's CureVac. US President Donald Trump has tried to drag the organization to the United States. In addition, Europe has announced to spend 8 billion dollar on vaccine research.

The ‘New York Times’ reports that no vaccines have been approved. It is unknown at this time what he will do after leaving the post. However, the United States has agreed with Pfizer to ensure priority for vaccination. Pfizer authorities say they will produce 100 million doses of the vaccine by December if the vaccine proves effective.

According to the agreement, Pfizer's vaccine will cost 20 US dollar per dose. They will receive doses of the first batch of vaccines. However, US citizens will receive the vaccine free of charge. However, the vaccine must be approved by the Food and Drug Administration. The US condition is that they will pay only if the vaccine is safe and understands 100 million doses.

According to Pfizer, large-scale testing of the vaccine has begun this month to prove it is safe and effective. Regulators will review its results by October. But so far nothing is certain.

Pfizer and Bio n Tech, as well as Oxford University, announced the results of the initial phase of their vaccination. They claim that their vaccine has been shown to be safe in the patient's body and has shown an immune response. The Pfizer vaccine also showed a high T-cell response to fight coronavirus.

Earlier, on July 1, Pfizer reported positive results from an experimental vaccine against COVID-19. They claim that it increases immunity in healthy people. It has produced antibodies against the SARS-Cov-2 virus. These antibodies contain antibodies that are effective in neutralizing or neutralizing viruses. The neutralizing antibodies produced in the body of a person recovering from Covid-19 disease are 1.8 to 2.8 times higher. However, if it is given in high doses, other side effects including fever occur.

The company is showing enough confidence to make a successful vaccine. In an interview with Time Online, Albert Borla, Pfizer's chief executive officer (CEO), said they hoped to get approval from the Food and Drug Administration for their vaccine by next October. They will know the effectiveness of the vaccine in September.

More than 150 vaccines are being developed and tested worldwide. There are currently 23 vaccines being administered experimentally to humans, including the Modern and AstraZeneca vaccines. However, experts warn that it takes 12 to 18 months to develop a safe and effective vaccine.


This website uses cookies

As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

Show Details
HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
LoginThis is necessary to sign in to the HubPages Service.
Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
AkismetThis is used to detect comment spam. (Privacy Policy)
HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
MavenThis supports the Maven widget and search functionality. (Privacy Policy)
Google AdSenseThis is an ad network. (Privacy Policy)
Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
Index ExchangeThis is an ad network. (Privacy Policy)
SovrnThis is an ad network. (Privacy Policy)
Facebook AdsThis is an ad network. (Privacy Policy)
Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
AppNexusThis is an ad network. (Privacy Policy)
OpenxThis is an ad network. (Privacy Policy)
Rubicon ProjectThis is an ad network. (Privacy Policy)
TripleLiftThis is an ad network. (Privacy Policy)
Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)
ClickscoThis is a data management platform studying reader behavior (Privacy Policy)